|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
miR-1228 functions as an oncogene by promoting cell cycle progression and cell mobility and negatively regulates the expression of p53. p53 downregulation in turn leads to an increase in miR-1228 expression, thereby forming a positive feedback loop that contributes to cancerogenesis in HCC.
|
25422913 |
2015 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
In this study, we described an alternative strategy named as trans-splicing that repaired mutant p53 transcripts in hepatocellular carcinoma (HCC) cells.
|
25732051 |
2015 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Using the MiSeq™ system, plasma and matched tumor DNA samples were analyzed for hotspot mutations in the TERT, CTNNB1, and TP53 genes that had been verified as the most prevalent mutations in HCC.
|
27248174 |
2016 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Since FBP1 suppresses p53 activity and is overexpressed in most HCC tumors, it may have a possible role in tumorigenesis.
|
25487856 |
2014 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We also used these methods to search for mutations in the P53 gene in patients with hepatocellular carcinoma.
|
10533071 |
1999 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that alterations of p53 may be important events in the genesis of HCCs and that point mutation may precede allele loss.
|
1311638 |
1992 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
In this study, we have examined the ability of HBx to modify p53 regulation of the HCC tumor marker gene, alpha-fetoprotein (AFP).
|
10842185 |
2000 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
To detect p53 mutations in circulating DNA (cirDNA) of transplanted hepatocellular carcinoma (HCC) patients could be an interesting approach to know of any tumor recurrence.
|
27753013 |
2016 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Hepatitis B virus integration event in human chromosome 17p near the p53 gene identifies the region of the chromosome commonly deleted in virus-positive hepatocellular carcinomas.
|
1670994 |
1991 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Conclusion: This study sheds light on the tumor suppressor role of lncRNA PSTAR, a modulator of the p53 pathway, in HCC.
|
31148184 |
2020 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Mutations of the tumor-suppressor gene p53 have been found in 30-50% cases of hepatocellular carcinoma (HCC).
|
10402169 |
1999 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
In vitro, Transwell and doxorubicin (DOX)-induced apoptosis assays revealed that GSTM1 showed opposite functions in different HCC cell lines with varied TP53 genotype statuses.
|
31605953 |
2019 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Mutant p53 protein was detected in the nuclei of HCCs from 14 (61%) of 23 patients from China and from three (30%) of 10 patients and six (60%) of 10 patients, respectively, from the two regions of the United States.
|
1279184 |
1992 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
LncRNA PLAC2 upregulates p53 to induce hepatocellular carcinoma cell apoptosis.
|
31233763 |
2019 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We searched for pathogenic variants in TP53 in a 14 year-old female diagnosed with fibrolamellar hepatocellular carcinoma, a rare subtype of hepatocellular carcinoma.
|
28477317 |
2018 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
In this study, we report that the haplo-insufficient tumor suppressor ASPP2, a p53 activator, negatively regulates the mevalonate pathway to mediate its inhibitory effect on tumor growth in hepatocellular carcinoma (HCC).
|
31685796 |
2019 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Centrosome aberration accompanied with p53 mutation can induce genetic instability in hepatocellular carcinoma.
|
15044920 |
2004 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
FASAY is a sensitive method for detecting the various types of p53 mutations in HCC, suggesting that the yeast functional assay for the detection of p53 mutations may be essential for elucidating their clinical significance.
|
17266182 |
2007 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Moreover, the expression of SIRT1, c-Myc and p53 were independent prognostic indicators of hepatocellular carcinoma.
|
23024800 |
2012 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Because our results suggest for the first time that the Pro/Pro homozygote of p53 Arg72Pro polymorphism may be a genetic susceptibility factor for HCC (especially in the male gender and HBV-infected patients) in the Turkish population, further independent studies are required to validate our findings in a larger series, as well as in patients of different ethnic origins.
|
21607615 |
2012 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Induction of apoptosis in hepatocellular carcinoma Smmc-7721 cells by vitamin K(2) is associated with p53 and independent of the intrinsic apoptotic pathway.
|
20449638 |
2010 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Analysis of the cellular origin of hepatocellular carcinoma by p53 genotype.
|
8954175 |
1996 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
In this study, we examined PICT1 expression levels and the status of TP53 in 51 primary HCC tissues in order to determine the clinical significance of PICT1 expression and the function of PICT1 in HCC cells.
|
23532381 |
2013 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
The nuclear localization of p53 is inhibited by GSN overexpression in hepatocarcinoma HepG2 cells.
|
21801713 |
2011 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
These findings show that p53 mutations are infrequently involved in the malignant transformation of hepatocytes in an area of low hepatocellular carcinoma prevalence.
|
1332921 |
1992 |